Possibilities of using topical (intranasal) solution of framycetin in the treatment of inflammatory pathology of the nasal cavity and nasopharynx in children 3–9 years old

Relevance. Topical antimicrobial agents (TAAs) have been used for many years to treat infections of various organs and systems, acting directly at the site of inflammation and providing a high local concentration in the absence of side/undesirable effects often associated with the use of systemic antibacterial agents. TAAs are included in the clinical guidelines of professional medical communities not only in combination with systemic antibacterial agents, but also as an alternative method of treatment (especially in otorhinolaryngology).

Aim. To evaluate the clinical efficacy of a solution for intranasal use based on framycetin of Russian (Tramicent^®) and foreign (Isofra^®) production in the complex therapy of patients with rhinopharyngitis and rhinosinusitis.

Materials and methods. The study included children aged 3 to 9 years who applied for an outpatient appointment with an otorhinolaryngologist for nasal congestion and/or discharge and did not require hospitalization for the underlying disease. All patients were prescribed treatment: sea water solutions for irrigation of the nasal mucosa in combination with intranasal TAA framycetin: Russian-made framycetin was used in children of group 1 (Tramicent^®), in children of group 2 – foreign production (Isofra^®). 7 days after the initial examination, the state of nasal breathing, rhinoscopic picture, dynamics of disease symptoms and satisfaction with the treatment of parents/legal representatives were assessed.

Results. The study included 61 patients aged 3 to 9 years (31 boys and 30 girls) with diagnoses of rhinopharyngitis (68%) and rhinosinusitis (32%). Comparison of the evaluated symptoms in patients on day 0 and day 7 showed that both drugs had a positive therapeutic effect: a statistically significant difference was noted in both groups for all studied symptoms on day 0 versus day 7 (p<0.05). Patients and/or their parents/legal representatives subjectively assessed the effectiveness of treatment with both drugs as “satisfied” and “very (very) satisfied”, no statistically significant difference was found (p=0.1987).

Discussion. The use of a Russian drug based on framycetin, in comparison with its foreign analogue, showed comparable clinical efficacy for all indicators evaluated in this study, with the exception of the symptom «nasal cavity edema». Subjective assessment of the treatment performed by parents/legal representatives of children also did not reveal a statistically significant difference in the use of framycetin produced in Russia and abroad (p=0.1987).

Conclusion. A Russian-made drug based on framycetin is not inferior in clinical efficacy to a foreign analogue, it is safe and can be used in treatment regimens for infectious and inflammatory pathologies of the nasal cavity and nasopharynx in children aged 3 to 9 years.